Heron Therapeutics | HRTX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
ALKERMES USD 1.75B 1.43B 2026-03
Alnylam Pharmaceuticals USD 898.54M 66.78M 2026-03
Amarin USD 51.48M 113K 2025-12
ANI Pharmaceuticals USD 562.3M 344.37M 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 215M 8.23M 2026-03
Eisai JPY 215.74B 15.84B 2026-03
Emergent BioSolutions USD 555.9M 242.7M 2023-06
Esperion Therapeutics USD 83.21M 14.06M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Heron Therapeutics USD 40.55M 1.46M 2025-12
Insmed USD 506.24M 7.31M 2026-03
Ligand Pharmaceuticals USD 34.35M 5.27M 2026-03
Merck USD 18.17B 8.01B 2026-03
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Neurocrine Biosciences USD 599.9M 22.3M 2026-03
Omeros USD 59.16M 20.13M 2024-06
Pacira USD 172.75M 20.93M 2026-03
Regeneron Pharmaceuticals USD 31.42B 28.44B 2026-03
Roche Holding CHF 21.01B 10.84B 2025-12
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Ultragenyx Pharmaceutical USD 305M 16M 2026-03
Veracyte USD 119.99M 3.99M 2026-03
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03